The development of androgen-independent prostate cancer (original) (raw)

• Greenlee, R. T., Taylor, M., Bolden, S. & Wingo, P. A. Cancer statistics: 2000. CA Cancer J. Clin. 50, 7–33 (2000).
  CAS PubMed Google Scholar
• Huggins, C. Endocrine-induced regression of cancers. Cancer Res. 27, 1925–1930 (1967).
  CAS PubMed Google Scholar
• Denmeade, S. R., Lin, X. S. & Isaacs, J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28, 251–265 (1996).
  CAS PubMed Google Scholar
• Griffin, J. E. & Wilson, J. D. in Williams Testbook of Endocrinology 9th edn (eds Wilson, J. D., Foster, D. W., Kronenberg, H. M. & Larsen, P. R.) 819–876 (W. B. Saunders & Co., Philadelphia, 1998).
  Google Scholar
• Quigley, C. A. et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16, 271–321.
• Brinkmann, A. O. et al. Mechanisms of androgen receptor activation and function. J. Steroid Biochem. Mol. Biol. 69, 307–313 (1999).
  CAS PubMed Google Scholar
• Nazareth, L. V. & Weigel, N. L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 271, 19900–19907 (1996).
  CAS PubMed Google Scholar
• McKenna, N. J., Lanz, R. B. & O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20, 321–344 (1999).
  CAS PubMed Google Scholar
• Howell, S. B. DNA microarrays for analysis of gene expression. Mol. Urol. 3, 295–300 (1999).
  CAS PubMed Google Scholar
• Ruijter, E. et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 20, 22–45 (1999). An extensive review of the mutations found in prostate cancers.
  CAS PubMed Google Scholar
• Lee, W. H. et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91, 11733–11737 (1994).
  CAS PubMed PubMed Central Google Scholar
• Hyytinen, E. R. et al. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br. J. Cancer 75, 190–195 (1997).
  CAS PubMed PubMed Central Google Scholar
• Pilat, M. J., Kamradt, J. M. & Pienta, K. J. Hormone resistance in prostate cancer. Cancer Metastasis Rev. 17, 373–381 (1998).
  CAS PubMed Google Scholar
• Marcelli, M. et al. Androgen receptor mutations in prostate cancer. Cancer Res. 60, 944–949 (2000). Analysed a large number of prostate cancers confirming the high frequency of AR mutations in AIPC.
  CAS PubMed Google Scholar
• Koivisto, P. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314–319.
• Taplin, M. E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393–1398 (1995). Raised the possibility of frequent AR mutations in metastatic prostate cancer.
  CAS PubMed Google Scholar
• Tilley, W. D., Buchanan, G., Hickey, T. E. & Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2, 277–285 (1996).
  CAS PubMed Google Scholar
• Taplin, M. E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 2511–2515 (1999).
  CAS PubMed Google Scholar
• Culig, Z. et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35, 63–70 (1998).
  CAS PubMed Google Scholar
• Craft, N. et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 59, 5030–5036 (1999).
  CAS PubMed Google Scholar
• Buchanan, G. et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res. 7, 1273–1281 (2001). Description of precocious AR mutations in human and TRAMP models and analysis of the types of mutation that stimulate AR signalling.
  CAS PubMed Google Scholar
• Buchanan, G. et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 15, 46–56 (2001).
  CAS PubMed Google Scholar
• Cher, M. L. et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56, 3091–3102 (1996).
  CAS PubMed Google Scholar
• Bruchovsky, N. et al. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol. Urol. 4, 191–199; discussion 201 (2000).
  CAS PubMed Google Scholar
• Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9, 401–406 (1995). This study defined the amplified AR as a mechanism for the hypersensitive pathway.
  CAS PubMed Google Scholar
• Palmberg, C. et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J. Urol. 164, 1992–1995 (2000).
  CAS PubMed Google Scholar
• Gregory, C. W., Johnson, R. T. Jr, Mohler, J. L., French, F. S. & Wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892–2898.
• Gregory, C. W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315–4319 (2001).
  CAS PubMed Google Scholar
• Labrie, F. et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr. Rev. 7, 67–74 (1986). An early review of the endocrinology and hormonal treatment of prostate cancer.
  CAS PubMed Google Scholar
• Makridakis, N. et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res. 57, 1020–1022 (1997).
  CAS PubMed Google Scholar
• Labrie, F. et al. Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 16, 475–492 (1993).
  CAS PubMed Google Scholar
• Eisenberger, M. A. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339, 1036–1042 (1998).
  CAS PubMed Google Scholar
• Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491–1498 (2000).
• Collette, L., Studer, U. E., Schroder, F. H., Denis, L. J. & Sylvester, R. J. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences. Prostate 48, 29–39 (2001).
  CAS PubMed Google Scholar
• Liotta, L. & Petricoin, E. Molecular profiling of human cancer. Nature Rev. Genet. 1, 48–56 (2000).
  CAS PubMed Google Scholar
• Veldscholte, J. et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol. 41, 665–669 (1992). Early definition of the LNCaP mutation that laid the foundations for understanding the promiscuous AR mechanism.
  CAS PubMed Google Scholar
• Gaddipati, J. P. et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861–2864 (1994).
  CAS PubMed Google Scholar
• Culig, Z. et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 7, 1541–1550 (1993).
  CAS PubMed Google Scholar
• Small, E. J. & Srinivas, S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76, 1428–1434 (1995).
  CAS PubMed Google Scholar
• Gottlieb, B. et al. The Androgen Receptor Gene Mutations Database. Nucleic Acids Res. 26, 234–238 (1998).
  CAS PubMed PubMed Central Google Scholar
• Matias, P. M. et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. J. Biol. Chem. 275, 26164–26171 (2000).
  CAS PubMed Google Scholar
• Sack, J. S. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl Acad. Sci. USA 98, 4904–4909 (2001).
  CAS PubMed PubMed Central Google Scholar
• McDonald, S., Brive, L., Agus, D. B., Scher, H. I. & Ely, K. R. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 60, 2317–2322 (2000).
  CAS PubMed Google Scholar
• Navone, N. M. et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 3, 2493–2500 (1997).
  CAS PubMed Google Scholar
• Zhao, X. Y. et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nature Med. 6, 703–706 (2000). Defined the double AR mutation creating a cortisol-responsive prostate cancer cell, expanding the promiscuous AR hypothesis to include circulating levels of corticosteroids.
  CAS PubMed Google Scholar
• Zhao, X. Y. et al. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J. Urol. 162, 2192–2199 (1999).
  CAS PubMed Google Scholar
• Suzuki, H. et al. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 46, 759–765 (1993).
  CAS PubMed Google Scholar
• Han, G. et al. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J. Biol. Chem. 276, 11204–11213 (2001).
  CAS PubMed Google Scholar
• Thalmann, G. N. et al. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91–103 (2000).
  CAS PubMed Google Scholar
• Culig, Z. et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 81, 242–251 (1999).
  CAS PubMed PubMed Central Google Scholar
• Adachi, M. et al. Androgen-insensitivity syndrome as a possible coactivator disease. N. Engl. J. Med. 343, 856–862 (2000).
  CAS PubMed Google Scholar
• Anzick, S. L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965–968 (1997).
  CAS PubMed Google Scholar
• Yeh, S. & Chang, C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc. Natl Acad. Sci. USA 93, 5517–5521 (1996).
  CAS PubMed PubMed Central Google Scholar
• Alen, P. et al. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform. Mol. Endocrinol. 13, 117–128 (1999).
  CAS PubMed Google Scholar
• Gao, T., Brantley, K., Bolu, E. & McPhaul, M. J. RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol. Endocrinol. 13, 1645–1656 (1999).
  CAS PubMed Google Scholar
• Miyamoto, H., Yeh, S., Wilding, G. & Chang, C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc. Natl Acad. Sci. USA 95, 7379–7384 (1998).
  CAS PubMed PubMed Central Google Scholar
• Lavinsky, R. M. et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl Acad. Sci. USA 95, 2920–2925 (1998).
  CAS PubMed PubMed Central Google Scholar
• McGuire, W. L., Chamness, G. C. & Fuqua, S. A. Estrogen receptor variants in clinical breast cancer. Mol. Endocrinol. 5, 1571–1577 (1991).
  CAS PubMed Google Scholar
• Culig, Z. et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474–5478 (1994). Early description of growth-factor activation of AR in the absence of ligand, developing the basis for the outlaw AR pathway.
  CAS PubMed Google Scholar
• Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
  CAS PubMed Google Scholar
• Borg, A. et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 81, 137–144 (1994).
  CAS PubMed Google Scholar
• Pietras, R. J. et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10, 2435–2446 (1995).
  CAS PubMed Google Scholar
• Craft, N., Shostak, Y., Carey, M. & Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Med. 5, 280–285 (1999). A leading example of the outlaw pathway with implications for the treatment of some cases of prostate cancer with Herceptin.
  CAS PubMed Google Scholar
• Yeh, S. et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl Acad. Sci. USA 96, 5458–5463 (1999).
  CAS PubMed PubMed Central Google Scholar
• Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  CAS PubMed Google Scholar
• Vogel, C. et al. First-line, single-agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 37, S25–S29 (2001).
  CAS PubMed Google Scholar
• Agus, D. B. et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 59, 4761–4764 (1999).
  CAS PubMed Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  CAS PubMed Google Scholar
• Ittmann, M. M. Chromosome 10 alterations in prostate adenocarcinoma. Oncol. Rep. 5, 1329–1335 (1998).
  CAS PubMed Google Scholar
• Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three AKTs. Genes Dev. 13, 2905–2927 (1999).
  CAS PubMed Google Scholar
• Stambolic, V. et al. Negative regulation of PKB/AKT-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29–39 (1998).
  CAS PubMed Google Scholar
• Wu, X., Senechal, K., Neshat, M. S., Whang, Y. E. & Sawyers, C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 95,15587–15591 (1998).
  CAS PubMed PubMed Central Google Scholar
• Maehama, T. & Dixon, J. E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9, 125–128 (1999).
  CAS PubMed Google Scholar
• Zhou, H., Li, X. M., Meinkoth, J. & Pittman, R. N. AKT regulates cell survival and apoptosis at a postmitochondrial level. J. Cell Biol. 151, 483–494 (2000).
  CAS PubMed PubMed Central Google Scholar
• Medema, R. H., Kops, G. J., Bos, J. L. & Burgering, B. M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782–787 (2000).
  CAS PubMed Google Scholar
• Graff, J. R. et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 275, 24500–24505 (2000).
  CAS PubMed Google Scholar
• Wen, Y. et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the AKT pathway. Cancer Res. 60, 6841–6845 (2000).
  CAS PubMed Google Scholar
• Zhou, B. P. et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the AKT/NF- κB pathway. J. Biol. Chem. 275, 8027–8031 (2000).
  CAS PubMed Google Scholar
• Signoretti, S. et al. HER-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. 92, 1918–1925 (2000).
  CAS PubMed Google Scholar
• Campbell, R. A. et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817–9824 (2001).
  CAS PubMed Google Scholar
• McDonnell, T. J. et al. Expression of the protooncogene BCL-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940–6944 (1992). Raised BCL2 overexpression as a potential example of the bypass pathway.
  CAS PubMed Google Scholar
• Colombel, M. et al. Detection of the apoptosis-suppressing oncoprotein Bcl2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143, 390–400 (1993).
  CAS PubMed PubMed Central Google Scholar
• Liu, A. Y., Corey, E., Bladou, F., Lange, P. H. & Vessella, R. L. Prostatic cell lineage markers: emergence of Bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int. J. Cancer 65, 85–89 (1996).
  CAS PubMed Google Scholar
• Gleave, M. et al. Progression to androgen independence is delayed by adjuvant treatment with antisense BCL-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin. Cancer Res. 5, 2891–2898 (1999).
  CAS PubMed Google Scholar
• Furuya, Y., Krajewski, S., Epstein, J. I., Reed, J. C. & Isaacs, J. T. Expression of BCL-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 2, 389–398.
• Isaacs, J. T. The biology of hormone refractory prostate cancer. Why does it develop? Urol. Clin. North Am. 26, 263–273 (1999). Expounded the lurker cell hypothesis.
  CAS PubMed Google Scholar
• Bui, M. & Reiter, R. E. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev. 17, 391–399 (1998).
  CAS PubMed Google Scholar
• Estrov, Z. et al. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 8, 46–52 (1994).
  CAS PubMed Google Scholar
• Davi, F., Gocke, C., Smith, S. & Sklar, J. Lymphocytic progenitor cell origin and clonal evolution of human B-lineage acute lymphoblastic leukemia. Blood 88, 609–621 (1996).
  CAS PubMed Google Scholar
• Morris, M. J. & Scher, H. I. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 89, 1329–1348 (2000).
  CAS PubMed Google Scholar
• Mendelsohn, L. G. Prostate cancer and the androgen receptor: strategies for the development of novel therapeutics. Prog. Drug Res. 55, 213–233 (2000).
  CAS PubMed Google Scholar
• Gleave, M. E., Miayake, H., Goldie, J. Nelson, C. & Tolcher, A. Targeting BCL-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense BCL-2 oligodeoxynucleotides. Urology 54, 36–46 (1999).
  CAS PubMed Google Scholar
• Kurita. T. et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ. 8, 192–200 (2001).
  CAS PubMed Google Scholar
• Chung, L. W. The role of stromal–epithelial interaction in normal and malignant growth. Cancer Surv. 23, 33–42 (1995).
  CAS PubMed Google Scholar
• Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339, 1609–1618 (1998).
  CAS PubMed Google Scholar